| Literature DB >> 29979199 |
Sarah Armour1, Trygve K Armour1, William R Joppa2, Simon Maltais3, James A Nelson1, Erica Wittwer1.
Abstract
Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.Entities:
Year: 2019 PMID: 29979199 DOI: 10.1213/ANE.0000000000003648
Source DB: PubMed Journal: Anesth Analg ISSN: 0003-2999 Impact factor: 5.108